Brown Advisory Inc. Buys 18,478 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Brown Advisory Inc. grew its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 0.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,173,833 shares of the medical research company's stock after acquiring an additional 18,478 shares during the quarter. Brown Advisory Inc. owned 1.39% of Edwards Lifesciences worth $592,439,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Bank Hapoalim BM lifted its position in shares of Edwards Lifesciences by 7.5% during the 1st quarter. Bank Hapoalim BM now owns 30,460 shares of the medical research company's stock valued at $2,208,000 after acquiring an additional 2,120 shares during the period. Ninety One SA PTY Ltd increased its position in shares of Edwards Lifesciences by 173.1% in the first quarter. Ninety One SA PTY Ltd now owns 144,984 shares of the medical research company's stock worth $10,459,000 after purchasing an additional 91,888 shares during the period. Argentarii LLC raised its stake in Edwards Lifesciences by 268.8% in the first quarter. Argentarii LLC now owns 12,732 shares of the medical research company's stock valued at $923,000 after purchasing an additional 9,280 shares in the last quarter. Concurrent Investment Advisors LLC lifted its position in Edwards Lifesciences by 37.1% during the first quarter. Concurrent Investment Advisors LLC now owns 26,909 shares of the medical research company's stock worth $1,950,000 after purchasing an additional 7,283 shares during the period. Finally, HM Payson & Co. grew its stake in Edwards Lifesciences by 2.9% during the first quarter. HM Payson & Co. now owns 7,121 shares of the medical research company's stock worth $516,000 after buying an additional 200 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Truist Financial dropped their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Citigroup reaffirmed a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Wall Street Zen cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Finally, Evercore ISI upped their price objective on Edwards Lifesciences from $73.00 to $77.00 and gave the stock an "in-line" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $80.40.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the company's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the sale, the vice president owned 33,496 shares of the company's stock, valued at approximately $2,514,879.68. This represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the transaction, the chief financial officer directly owned 41,098 shares of the company's stock, valued at approximately $3,057,691.20. This trade represents a 21.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,348 shares of company stock valued at $2,977,683 over the last three months. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Down 0.9%

EW traded down $0.73 during midday trading on Friday, hitting $78.07. 3,780,176 shares of the company were exchanged, compared to its average volume of 5,256,833. The firm has a market capitalization of $45.79 billion, a P/E ratio of 11.15, a P/E/G ratio of 3.96 and a beta of 1.11. The firm's 50 day moving average price is $76.30 and its 200-day moving average price is $73.38. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1-year low of $58.93 and a 1-year high of $92.88.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm's quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.66 earnings per share. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.